MoneyWorks4Me

Lupin informs about press release

06 Sep 2021 Evaluate

Lupin has informed that it enclosed is a press release on 6th September 2021 as regards granting of a non-exclusive license to the Company to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen, by Non-profit drug developer, TB Alliance. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..